TARA vs. TSBX, ENTX, ATRA, IKNA, CSBR, CVM, TIL, CDTX, GNTA, and CGTX Should you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include Turnstone Biologics (TSBX), Entera Bio (ENTX), Atara Biotherapeutics (ATRA), Ikena Oncology (IKNA), Champions Oncology (CSBR), CEL-SCI (CVM), Instil Bio (TIL), Cidara Therapeutics (CDTX), Genenta Science (GNTA), and Cognition Therapeutics (CGTX). These companies are all part of the "biological products, except diagnostic" industry.
Protara Therapeutics (NASDAQ:TARA ) and Turnstone Biologics (NASDAQ:TSBX ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.
38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 52.5% of Turnstone Biologics shares are held by institutional investors. 18.4% of Protara Therapeutics shares are held by insiders. Comparatively, 32.1% of Turnstone Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Protara Therapeutics and Protara Therapeutics both had 4 articles in the media. Protara Therapeutics' average media sentiment score of 0.39 beat Turnstone Biologics' score of -0.78 indicating that Protara Therapeutics is being referred to more favorably in the media.
Protara Therapeutics received 29 more outperform votes than Turnstone Biologics when rated by MarketBeat users. Likewise, 63.27% of users gave Protara Therapeutics an outperform vote while only 50.00% of users gave Turnstone Biologics an outperform vote.
Protara Therapeutics has higher earnings, but lower revenue than Turnstone Biologics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Turnstone Biologics, indicating that it is currently the more affordable of the two stocks.
Protara Therapeutics currently has a consensus price target of $26.50, indicating a potential upside of 757.61%. Turnstone Biologics has a consensus price target of $19.00, indicating a potential upside of 614.29%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Protara Therapeutics is more favorable than Turnstone Biologics.
Protara Therapeutics' return on equity of -58.80% beat Turnstone Biologics' return on equity.
Summary Protara Therapeutics beats Turnstone Biologics on 9 of the 13 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Protara Therapeutics Competitors List
Related Companies and Tools
